-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-06-26
IQV:NYE- (USD)
COMMON STOCK | Diagnostics & Research |
Last Closing
USD 211.18Change
-0.24 (-0.11)%Market Cap
USD 39.03BVolume
1.66MVerdict
Verdict
Values as of: 2024-06-26
COMMON STOCK | Diagnostics & Research |
Last Closing
USD 211.18Change
-0.24 (-0.11)%Market Cap
USD 39.03BVolume
1.66MVerdict
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
TMO | Thermo Fisher Scientific Inc |
+2.22 (+0.40%) |
USD 215.52B |
DHR | Danaher Corporation |
-1.91 (-0.76%) |
USD 188.85B |
A | Agilent Technologies Inc |
-1.17 (-0.89%) |
USD 37.82B |
MTD | Mettler-Toledo International I.. |
-8.93 (-0.63%) |
USD 31.26B |
LH | Laboratory Corporation of Amer.. |
-1.39 (-0.68%) |
USD 17.57B |
WAT | Waters Corporation |
+3.65 (+1.27%) |
USD 17.22B |
DGX | Quest Diagnostics Incorporated |
-0.46 (-0.33%) |
USD 15.40B |
RVTY | Revvity Inc. |
-0.85 (-0.80%) |
USD 13.32B |
CRL | Charles River Laboratories |
-0.77 (-0.37%) |
USD 10.90B |
QGEN | Qiagen NV |
-0.01 (-0.02%) |
USD 9.71B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
EKG | First Trust Nasdaq Lux Di.. | 6.96 % | 0.00 % |
-0.13 (0.26%) |
USD 2.38M |
XYLP:LSE | Global X S&P 500® Covere.. | 4.70 % | 0.00 % |
+0.03 (+0.26%) |
USD 0.02B |
ASRP:XETRA | BNP Paribas Easy ECPI Glo.. | 2.23 % | 0.00 % |
-0.04 (0.26%) |
USD 0.04B |
MEDTE:PA | BNP Paribas Easy ECPI Glo.. | 2.23 % | 0.00 % |
N/A |
N/A |
MTUSD:PA | BNP Paribas Easy ECPI Glo.. | 2.23 % | 0.00 % |
N/A |
N/A |
BBH | VanEck Biotech ETF | 0.00 % | 0.35 % |
-1.60 (0.26%) |
USD 0.43B |
GNRX | 0.00 % | 0.55 % |
N/A |
N/A | |
IBB | iShares Biotechnology ETF | 0.00 % | 0.47 % |
-0.65 (0.26%) |
USD 7.43B |
PBI | Pitney Bowes Inc | 0.00 % | 0.79 % |
+0.17 (+0.26%) |
USD 0.85B |
HIG:CA | Global Healthcare Income .. | 0.00 % | 1.02 % |
N/A |
CAD 0.05B |
ZHU:CA | BMO Equal Weight US Healt.. | 0.00 % | 0.00 % |
-0.13 (0.26%) |
CAD 0.05B |
MID | American Century Mid Cap .. | 0.00 % | 0.00 % |
-0.20 (0.26%) |
USD 0.07B |
VNMC | Natixis ETF Trust II - Na.. | 0.00 % | 0.00 % |
+0.09 (+0.26%) |
USD 4.19M |
Market Performance vs. Industry/Classification (Diagnostics & Research) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | -8.73% | 54% | F | 19% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -8.73% | 46% | F | 17% | F | ||
Trailing 12 Months | |||||||
Capital Gain | -3.67% | 46% | F | 25% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -3.67% | 46% | F | 21% | F | ||
Trailing 5 Years | |||||||
Capital Gain | 31.25% | 36% | F | 64% | D | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 31.25% | 36% | F | 55% | F | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 14.43% | 62% | D | 79% | B- | ||
Dividend Return | 14.43% | 62% | D | 75% | C | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 29.18% | 62% | D | 36% | F | ||
Risk Adjusted Return | 49.46% | 62% | D | 71% | C- | ||
Market Capitalization | 39.03B | 85% | B | 94% | A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers median on a price to book value basis.